Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

Go online to PeerView.com/DQM860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you up to the challenge of selecting and sequencing BTK
inhibitor options in difficult B-cell cancer settings? This
PeerView MasterClass and Case Forum activity recorded at the
European hematology annual meeting explores BTK inhibitors as
highly effective therapeutic tools for treating R/R CLL/SLL and
MCL; join the experts and learn about important evidence on the
“upgraded” sequential use of BTK inhibitors and other therapeutic
innovations in pretreated B-cell cancer settings. Throughout, the
experts will provide case-based insights on the principles of BTK
inhibitor selection and sequencing in the setting of disease
progression, therapeutic intolerance, and other challenging
pretreated populations. Upon completion of this activity,
participants should be better able to: Cite barriers to effective
sequential therapy with BTK inhibitors, the mechanistic and
selectivity differences between covalent and non-covalent agents,
and current efficacy and safety evidence supporting individualized
BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer
settings; Develop safe, individualized, and evidence-based
sequential therapy plans that incorporate the use of BTK inhibitors
for patients with R/R CLL/SLL who have progressed on prior therapy;
Recommend appropriate BTK inhibitor therapy for patients with R/R
MCL or other B-cell malignancies that is informed by the principles
of sequential care, strategies to maximize safety, and the option
of clinical trial enrollment.